MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$183,527K
EPS
-$2.06
Unit: Thousand (K) dollars

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Income Statement
2025-12-31
Research and development
117,665
General and administrative
48,644
Total operating expenses
166,309
Loss from operations
-166,309
Interest income
10,960
Interest expense
5,482
Foreign exchange loss, net
-131
Change in fair value of 2022 usd financing warrants
22,831
Gain on extinguishment of contribution payable
0
Total other expense, net
-17,484
Net loss
-183,793
Unrealized gain on investments
330
Gain/(loss) on foreign currency translation
-64
Comprehensive loss
-183,527
Earnings per share, basic, total
-2.06
Earnings per share, diluted, total
-2.06
Weighted average number of shares outstanding, basic, total
89,327,608
Weighted average number of shares outstanding, diluted, total
89,327,608
Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$183,527K Unrealized gain oninvestments$330K Net loss-$183,793K Gain/(loss) on foreigncurrency translation-$64K Loss from operations-$166,309K Total other expense,net-$17,484K Interest income$10,960K Total operatingexpenses$166,309K Change in fair value of2022 usd financing...$22,831K Interest expense$5,482K Foreign exchange loss,net-$131K Research and development$117,665K General andadministrative$48,644K

Definium Therapeutics, Inc. (DFTX)

Definium Therapeutics, Inc. (DFTX)